Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.89 0.32 +0.47%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC (RPRX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a EV/Sales of 14.6×. Over the past ten years it has ranged from 0.0× (June 2020) to 14.6× (November 2026) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 10.5× 31.35%
FY2024 8.0× (2.64%)
FY2023 8.2× (19.02%)
FY2022 10.1× 7.15%
FY2021 9.4× (11.82%)
FY2020 10.7× —
FY2019 0.0× —
FY2018 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 13.0× (0.18%)
Jun 2026 13.0× 8.65%
Mar 2026 12.0× 14.57%
Dec 2025 10.5× 6.01%
25 more quarters

Against its own ten years

Low 0.0× High 14.6×
Ten-year median 9.5×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
INCY Incyte Corporation compare 3.4×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 5.9×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ARGX argenex SE compare 8.9×
RPRX Royalty Pharma PLC 14.6×
INSM Insmed, Inc. compare 15.4×
RVMD Revolution Medicines, Inc. compare 172×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on RPRX